-
A Study Of TAK-861 For The Treatment Of Selected Central Hypersomnia Conditions
Scottsdale/Phoenix, AZ
The main aim is to evaluate the safety and tolerability of TAK-861 on participants with type 1 narcolepsy, who were exposed to previously tested doses of TAK-861.
-
Study To Assess The Safety And Effectiveness Of Oral BTD-001 In Adults With Idiopathic Hypersomnia
Scottsdale/Phoenix, AZ; Rochester, MN
The purpose of this study is to evaluate the safety, tolerability and effectiveness of BTD-001 in subjects with idiopathic hypersomnia (IH) as reflected by changes in mental fogginess, sleep, functional, and quality-of-life measures.
-
A Phase 3 Study To Assess The Safety And Efficacy Of Pitolisant In Adult Patients With Idiopathic Hypersomnia
Scottsdale/Phoenix, AZ
The purpose of this study is to evaluate the safety and effectiveness of pitolisant compared with placebo in treating excessive daytime sleepiness (EDS) in patients with idiopathic hypersomnia (IH) age ≥ 18 years.
-
Low Sodium Oxybate In Patients With Idiopathic Hypersomnia
Scottsdale/Phoenix, AZ; Jacksonville, FL
The purpose of this study is to evaluate the effect of low sodium oxybate (LSO) on total sleep time as measured by 24-hour polysomnography.
The secondary objective of this study is to evaluate the effect of low sodium oxybate on total sleep time as measured by Nestsense EEG earbuds, Axivity device, and patient sleep diary entries.
An exploratory objective of this study is to evaluate the effect of low sodium oxybate on patient reported outcomes, micro/macro sleep stages, daily activity levels/steps, and degree of association between outcomes measured in the study.
-
A Study Of The Safety And Effectiveness Of JZP-110 In The Treatment Of Excessive Sleepiness In Patients With Narcolepsy
Scottsdale/Phoenix, AZ
The purpose of this study is to assess the safety and effectiveness of JZP-110 in the treatment of excessive sleepiness in adult subjects with narcolepsy.
-
Twelve-week Study Of The Safety And Efficacy Of JZP-110 In The Treatment Of Excessive Sleepiness In OSA
Scottsdale/Phoenix, AZ
This trial is a 12 week, randomized, double-blind, placebo controlled, multicenter, 5-arm parallel group study of safety and efficacy of JZP-110 in the treatment of excessive sleepiness in adult subjects with OSA.
-
A 4-Week Study Of The Safety, Efficacy, And Pharmacokinetics Of JZP-110 [(R)-2-amino-3-phenylpropylcarbamate Hydrochloride] In Subjects With Parkinson's Disease And Excessive Sleepiness
Scottsdale/Phoenix, AZ
This study is a 4-week, multicenter, randomized, double-blind, placebo-controlled, ascending dose, 4-period crossover study designed to evaluate the safety, tolerability, efficacy, and PK of JZP-110 (75, 150, and 300 mg) in the treatment of excessive sleepiness in adult subjects with idiopathic PD.
-
A Long-Term Safety Study Of JZP-110 In The Treatment Of Excessive Sleepiness In Subjects With Narcolepsy Or OSA
Scottsdale/Phoenix, AZ
This is a Phase 3 study to assess the long-term safety and maintenance of efficacy of JZP-110 in subjects who have completed Study 14-002, 14-003, 14-004, 15-004, 15-005, ADX-N05 201, or ADX-N05 202.
-
Does Narcolepsy/Idiopathic Hypersomnia and Their Treatment(s) Alter Blood Pressure and Cognition
Scottsdale/Phoenix, AZ; Rochester, MN
The objectives of this study are to demonstrate that patients with CNS hypersomnias exhibit cardiovascular and cognitive disturbances, and to demonstrate that CNS medications medications impact these cardiovascular and cognitive disturbances.